During the last session, AbCellera Biologics Inc (NASDAQ:ABCL)’s traded shares were 6.97 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stock’s price was $4.22, reflecting an intraday gain of 8.48% or $0.33. The 52-week high for the ABCL share is $4.11, that puts it up 2.61 from that peak though still a striking 55.21% gain since the share price plummeted to a 52-week low of $1.89. The company’s market capitalization is $1.26B, and the average intraday trading volume over the past 10 days was 6.71 million shares, and the average trade volume was 5.45 million shares over the past three months.
AbCellera Biologics Inc (ABCL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. ABCL has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
AbCellera Biologics Inc (ABCL) registered a 8.48% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.48% in intraday trading to $4.22, hitting a weekly high. The stock’s 5-day price performance is 20.92%, and it has moved by 72.95% in 30 days. Based on these gigs, the overall price performance for the year is 44.03%. The short interest in AbCellera Biologics Inc (NASDAQ:ABCL) is 26.52 million shares and it means that shorts have 4.66 day(s) to cover.
The consensus price target of analysts on Wall Street is $23.5, which implies an increase of 82.04% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $34 respectively. As a result, ABCL is trading at a discount of -705.69% off the target high and -18.48% off the low.
AbCellera Biologics Inc (ABCL) estimates and forecasts
In the rating firms’ projections, revenue will decrease -9.62% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.55M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 7.57M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 7.32M and 6.51M respectively. In this case, analysts expect current quarter sales to grow by 3.04% and then jump by 16.35% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -107.74%. While earnings are projected to return -11.29% in 2025, the next five years will return 0.83% per annum.
ABCL Dividends
AbCellera Biologics Inc is due to release its next quarterly earnings on 2025-May-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
AbCellera Biologics Inc insiders own 22.97% of total outstanding shares while institutional holders control 44.79%, with the float percentage being 58.14%. BAKER BROS. ADVISORS LP is the largest shareholder of the company, while 178.0 institutions own stock in it. As of 2024-06-30, the company held over 27.53 million shares (or 9.3556% of all shares), a total value of $81.48 million in shares.
The next largest institutional holding, with 21.91 million shares, is of BAILLIE GIFFORD & CO’s that is approximately 7.4472% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.86 million.
Also, the Mutual Funds coming in first place with the largest holdings of AbCellera Biologics Inc (ABCL) shares are SMALLCAP WORLD FUND INC and iShares Trust-iShares Biotechnology ETF . Data provided on Mar 31, 2025 indicates that SMALLCAP WORLD FUND INC owns about 13.36 shares. This amounts to just over 4.48 percent of the company’s overall shares, with a $56.38 million market value. The same data shows that the other fund manager holds slightly less at 1.33, or about 0.45% of the stock, which is worth about $5.61 million.
